From: The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?
Postoperative complications | Non-COVID group n = 2412 | COVID group n = 180 |
---|---|---|
Localized biliary peritonitis | 51 (2.1%) | 9 (5%) |
Pulmonary | 44 (1.82%) | 12 (6.6%) |
Wound infection | 39 (1.61%) | 15 (8.3%) |
Bleeding | 32 (1.32%) | 5 (2.7%) |
Intra-abdominal abscess | 26 (1.07%) | 1 (0.6%) |
Diffuse biliary peritonitis | 25 (1.03%) | 5 (2.7%) |
Biliary fistula | 19 (0.8%) | 2 (1.1% |
Sepsis/septic shock | 16 (0.07%) | 4 (2.2%) |
CBD stones | 14 (0.6%) | 1 (0.6%) |
Gastrointestinal | 9 (0.04%) | 1 (0.6%) |
Cardiac | 8 (0.03%) | 2 (1.1%) |
CBD injury | 7 (0.03%) | 1 (0.6%) |
Fever of unknown source | 7 (0.03%) | 2 (1.1%) |
Bowel perforation | 7 (0.03%) | 0 (0%) |
Localized collection | 5 (0.02%) | 0 (0%) |
Pancreatitis | 5 (0.02%) | 1 (0.6%) |
Renal | 3 (0.01%) | 1 (0.6%) |
Delerium/neurological | 3 (0.01%) | 3 (1.7%) |
Others | 14 (0.6%) | 1 (0.6%) |